P59.15 Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)?
Year: 2021
Type: conference-abstract
Source: Journal of Thoracic Oncology
Authors: I.J. Eide, A.P. Dyrbekk, Å. Helland, S. Ekman, J. Koivunen, S. Cicenas, B. Grønberg, I. Bisha, T. Haberichter, S. Lakis, J. Chan, A. Lewis, P. Martin, Z. Cooper, O.T. Brustugun
Institutions: Oslo University Hospital, University of Oslo, Karolinska University Hospital, Karolinska Institutet, Oulu University Hospital, University of Oulu, National Cancer Institute, Norwegian University of Science and Technology, AstraZeneca (United Kingdom), AstraZeneca (United States), Drammen Hospital, Vestre Viken Hospital Trust
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3207153731